Nebius Surges 85% into Peak Euphoria – Execution Risks Loom

What happened

Nebius Group has surged 85% since our last analysis, with Q1 revenue up 841%, but the stock now prices in flawless execution on multi-year capacity delivery and hyperscaler contracts. The DeepValue report maintains a WAIT rating, emphasizing that the 800MW–1GW connected power milestone by YE2026 and a Q3 capacity step-up are the true near-term proof points, not revenue momentum. At $221, the valuation (P/E 68) already discounts smooth deployment of Meta's $12B dedicated capacity beginning early 2027, leaving little room for the schedule slippage or dilution that filings explicitly permit. Dilution overhang from ~66M convertible shares and an unused ATM, combined with insider selling clusters, adds further downside risk if capital markets tighten or delivery falters. The next 6-9 months will determine whether the stock holds these levels or corrects to the $140 bear case.

Implication

Investors should wait for clear evidence of the Q3 capacity step-up and YE2026 power targets before adding, as downside risks from dilution and penalties are more material than missed revenue beats. At current levels, the risk/reward is unattractive, with the base case fair value at $235 but bear case at $140; trim into strength above $280 and look to accumulate near $180.

Thesis delta

The article reinforces the WAIT rating by quantifying the euphoria and elevated multiples, but does not alter the core thesis that execution proof in H2 2026 is the key catalyst. The risk of a sharp drawdown has increased given the speed of the run-up.